Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 3833
  • Home
  • Print this page
  • Email this page

   Table of Contents      
LETTER TO THE EDITOR
Year : 2018  |  Volume : 66  |  Issue : 2  |  Page : 349-350

Reply to comment on: Aflibercept for recurrent or recalcitrant polypoidal choroidal vasculopathy in Indian eyes: Early experience


1 Shri Bhagwan Mahavir Vitreoretinal Services, Sankara Nethralaya, Chennai, Tamil Nadu, India
2 Vitreoretinal Services, Aditya Birla Sankara Nethralaya, Kolkata, West Bengal, India

Date of Web Publication30-Jan-2018

Correspondence Address:
Muna Bhende
Sankara Nethralaya, 18/41, College Road, Nungambakam, Chennai - 600 006, Tamil Nadu
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijo.IJO_1093_17

Rights and Permissions

How to cite this article:
Bansal A, Bhende M, Sharma T, Bhende P, Mukherjee S. Reply to comment on: Aflibercept for recurrent or recalcitrant polypoidal choroidal vasculopathy in Indian eyes: Early experience. Indian J Ophthalmol 2018;66:349-50

How to cite this URL:
Bansal A, Bhende M, Sharma T, Bhende P, Mukherjee S. Reply to comment on: Aflibercept for recurrent or recalcitrant polypoidal choroidal vasculopathy in Indian eyes: Early experience. Indian J Ophthalmol [serial online] 2018 [cited 2020 Sep 20];66:349-50. Available from: http://www.ijo.in/text.asp?2018/66/2/349/224064



Sir,

We thank you for your interest in our paper and agree with your concerns.[1],[2] All the patients were treated at our institute from the beginning. The definition of recalcitrance/resistance has been mentioned in the text. As this is a retrospective analysis of patients followed over many years, some even before the introduction of antivascular endothelial growth factors in ophthalmology, it is not possible for us to fit all the cases into defined criteria for switching agents, stopping, or continuing treatment. The reason for introducing recurrent cases to aflibercept was to ascertain the possibility of achieving an end point in treatment or at least an increase in the treatment-free interval. Failure to achieve either of the two resulted in a switch back to the original drug as long as the eye had useful vision. We agree that financial issues are important which is why our study had only ten patients, those who could afford the injection and not all cases that were resistant or recalcitrant. This particular study was not intended to test the use of either aflibercept or ziv-aflibercept as primary treatment of polypoidal choroidal vasculopathy; hence, we would not like to extrapolate our results in that direction.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Kathiriya V, Kanhere M, Gala Y, Ramchandani S. Comment on: Aflibercept for recurrent or recalcitrant polypoidal choroidal vasculopathy in Indian eyes: Early experience. Indian J Ophthalmol 2018;66:348-9.  Back to cited text no. 1
  [Full text]  
2.
Bansal A, Bhende M, Sharma T, Bhende P, Mukherjee S. Aflibercept for recurrent or recalcitrant polypoidal choroidal vasculopathy in Indian eyes: Early experience. Indian J Ophthalmol 2017;65:758-60.  Back to cited text no. 2
[PUBMED]  [Full text]  




 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
References

 Article Access Statistics
    Viewed346    
    Printed1    
    Emailed0    
    PDF Downloaded100    
    Comments [Add]    

Recommend this journal